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Rapidly growing mycobacteria are non-tuberculous mycobacteria amply present in the environment. 
Although they are not usually pathogenic for humans, they are opportunistic in that they can cause 
disease in people with disadvantageous conditions or who are immunocompromised. Mycobacterium 
peregrinum, an opportunistic, rapidly growing mycobacteria, belongs to the M. fortuitum group and has 
been reported as responsible for human cases of mycobacteriosis. 
A case of M. peregrinum type III is herein reported as the first in Colombia. It presented as a 
disseminated disease involving a prosthetic aortic valve (endocarditis) in a seventeen-year-old girl 
with a well-established diagnosis of prosthetic aortic valve endocarditis who was referred for a surgical 
replacement. Due to a congenital heart disease (subaortic stenosis with valve insufficiency), she had 
two previous aortic valve implantation surgeries. One year after the second implantation, the patient 
presented with respiratory symptoms and weight lost indicative of lung tuberculosis.
A chest X-ray did not show parenchymal compromise but several Ziehl-Neelsen stains were positive. 
An echocardiography showed a vegetation on the prosthetic aortic valve. In blood and sputum samples, 
M. peregrinum type III was identified through culture, biochemical tests and hsp65 gene molecular 
analysis (PRA). The patient underwent a valve replacement and received a multidrug antimycobacterial 
treatment. Progressive recovery ensued and further samples from respiratory tract and blood were 
negative for mycobacteria.
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Micobacteriosis diseminada con compromiso de válvula aórtica protésica: primer caso de 
Mycobacterium peregrinum de tipo III reportada en Colombia
Las micobacterias de rápido crecimiento son microorganismos pertenecientes a las micobacterias no 
tuberculosas que tienen amplia distribución ambiental. Aunque usualmente no son patógenas para 
los humanos, en condiciones desfavorables, pueden causar enfermedad en la población general o en 
huéspedes inmunocomprometidos, por lo cual se consideran oportunistas. Mycobacterium preregrinum 
es una micobacteria de rápido crecimiento perteneciente al complejo fortuitum que ha sido reportado 
como responsable de casos de micobacteriosis en humanos. 
Se presenta el caso de una micobacteriosis por M. peregrinum de tipo III, el primero reportado en 
Colombia, en una paciente de 17 años de edad con una endocarditis de una válvula aórtica protésica, 
implantada inicialmente por estenosis subaórtica congénita con insuficiencia y, posteriormente, por 
estenosis aórtica relacionada con la válvula inicialmente implantada. Un año después del segundo 
implante, presentó sintomas respiratorios y pérdida de peso sugestivos de tuberculosis pulmonar. 
Las coloraciones de Ziehl-Neelsen del esputo fueron positivas aunque la radiografía de tórax no mostró 
compromiso del parénquima. En el ecocardiograma se encontró una vegetación en la válvula aórtica. 
En las muestras de sangre y de esputo, se identificó M. peregrinum de tipo III por cultivo, pruebas 
bioquímicas y análisis molecular del gen hsp65  por PCR-restriction pattern analysis (PRA).
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La paciente se sometió a cambio de válvula y recibió tratamiento combinado contra la micobacteria, 
con rápida recuperación. Las muestras tomadas del sistema respiratorio y sanguíneo se tornaron 
negativas para micobacterias.
Palabras clave: Mycobacterium, Mycobacterium peregrinum, válvula aórtica protésica, endocarditis, 
micobacterias de rápido crecimiento, infecciones por Mycobacterium, Colombia.
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The genus Mycobacterium comprises strictly 
pathogenic, opportunistic (potentially but not 
usually pathogenic), and non-pathogenic species. 
Opportunistic mycobacteria are commonly recovered 
from natural and human-influenced environments 
and can cause disease in humans and animals, 
especially birds. These characteristics reference 
them as environmental opportunistic mycobacteria 
or non-tuberculous mycobacteria (1,2). Environmental 
opportunistic mycobacteria include slowly growing 
mycobacteria (colonies usually visible after seven 
days, such as the Mycobacterium avium intracellulare 
complex) and rapidly growing mycobacteria (colonies 
usually visible less than seven days) (1,3).
Rapidly growing mycobacteria are classified in three 
groups: M. fortuitum, M. chelonae-M. abscessus 
and M. smegmatis (3). In clinical conditions, rapidly 
growing mycobacteria have been related to skin and 
soft tissue infections (frequently postsurgical wound 
infections), pulmonary disease, and colonization of 
implanted materials such as prosthetics, catheters 
and sutures; these infections could result in sepsis 
and disseminated disease (3-7). Clinical cases 
of environmental opportunistic mycobacteria, 
including rapidly growing mycobacteria, have been 
reported in Colombia (8-11).
Mycobacterium peregrinum, a rapidly growing 
mycobacterium belonging to the M. fortuitum 
group, has been reported as causing opportunistic 
disease in humans (3,12). Several past cases have 
had M peregrinum designated as the causative 
agen as a consequence of the reclassification of 
microorganisms initially described as M. fortuitum 
(3).
Herein, the first report of mycobacteriosis caused 
by M. peregrinum type III in Colombia is presented 
and, to the best of our knowledge, the first one 
affecting a prosthetic cardiac valve.
Clinical case
A seventeen-year old female patient, born in 
Arauca (Colombia), was referred to the Fundación 
Neumológica Colombiana-Fundación Cardioinfantil-
Instituto de Cardiología (Bogotá, Colombia) with a 
diagnosis of prosthetic aortic valve endocarditis. 
Fifteen years before, the patient had been diagnosed 
with a persistent ductus arteriosus and a mild 
perimembranous interventricular communication 
and 5 years later, with a subaortic stenosis with 
moderate insufficiency of the aortic valve. These 
abnormalities were corrected by surgical closure 
of the ductus and interventricular communication, 
subaortic ring widening and implantation of a 
mechanical aortic valve.
Four years later, she began to develop a progressive 
relative aortic valve stenosis, and at age 14, 12 
years after her initial diagnosis, her aortic valve was 
replaced by a mechanical valve. Two years later, the 
patient consulted because of persistent cough with 
hemoptoic sputum. A serial Ziehl-Neelsen (ZN) stain 
of the sputum was positive and an antituberculosis 
treatment with isoniazid (H), ethambutol (E) and 
rifampicin (R) was started. However, since the 
chest X-ray showed no parenchymal abnormalities 
and the ZN stain and culture of bronchoalveolar 
lavage was negative, the antituberculosis treatment 
was withdrawn. Eleven months later she presented 
with weakness and cough. A new ZN stain of the 
sputum was positive, again without parenchymal 
abnormalities. Antituberculosis treatment was 
restarted but complicated by a medicamentous 
hepatitis.
Six months later, the patient consulted because 
of lower limb pain, purpuric lesions suggesting 
vasculitis, left eye amaurosis, convulsive crisis, 
cough, and hemoptoic sputum. She was hospitalized 
at Fundación Cardiovascular de Colombia in 
Bucaramanga. An infectious endocarditis of her 
prosthetic valve was suspected and later confirmed 
by echocardiography. Direct stains and cultures 
for common microorganisms in blood, cerebral 
spinal fluid and sputum samples were negative. 
Collagen diseases were ruled out. A drug-resistant 
tuberculosis or non-tuberculous mycobacteria 
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infection were suspected. A treatment with 
ciprofloxacine, claritromicine and trimethoprim-
sulfamethoxazole was initiated, and due to non- 
medical reasons, the patient was referred to the 
Fundación Neumológica Colombiana-Fundación 
Cardioinfantil-Instituto de Cardiología for a new 
aortic valve replacement. A clinical diagnosis of 
infectious endocarditis was evident.
The physical examination showed a patient with 
deteriorated general condition, tachycardia, cardiac 
murmur, normal breath sounds, painful edema of 
the right knee, and purpuric lesions in the legs. No 
neurological abnormalities were found.
The hemogram showed normocytic normochromic 
anemia and normal count of white blood cells. 
Creatinine and transaminases levels were normal. 
The immunological profile and HIV serology were 
negative. A serial ZN stain of the sputum and blood 
cultures for common bacteria were also negative. 
The chest X-ray showed mild cardiomegaly 
with a mechanical aortic valve; neither lung 
abnormalities nor pleural effusions were found. The 
echocardiogram showed a 5 x 5 mm vegetation on 
the mechanical aortic valve, paravalvular leak and a 
saccular image suggesting abscess. The fiberoptic 
bronchoscopy was normal. The routine stains, 
including ZN stain, of the bronchoalveolar lavage 
were negative, but a significant lymphocytosis 
(81%) was found.
A rapidly growing mycobacteria was isolated in 
cultures from blood and sputum samples and sent 
to the Colombian National Institute of Health for 
phenotypical identification; pigment production was 
determined, as well as growth speed at 45° C, 37°C, 
32°C and 22°C. Enzymatic tests for catalases, 
nitrates, arylsulphatase, pyrazinamidase, urease, 
acid phosphatase, tween hydrolysis and niacin 
detection were performed. Additionally, growth or 
inhibition capacity was determined in MacConkey 
medium, 0.2% picric agar and Lowestein Jensen 
(LJ) medium for 10 ug/L tiofen-carboxylic acid 
hydrazide (TCH), 250 ug/L hydroxylamine (HA), 
and 5% sodium chloride; Molecular identification 
was done through gene hsp65 restriction analysis 
(PRA) (13,14), the patterns found for the BstEII 
enzyme were 240/130/85 and 145/140/100/60 for 
the HaeIII enzyme, resulting in M. peregrinum type 
III identification in blood and sputum samples.
A disseminated mycobacteriosis with aortic valve 
endocarditis due to M. peregrinum type III was 
diagnosed.
The treatment was adjusted including amikacin, 
imipenem, clarithromycin, trimethoprim-sulfametho-
xazole, rifampicin, and doxicicline and, a few days 
after, the patient was undergone to an implantation 
of a biological aortic valve with replacement of the 
ascending aorta and coronary re-implantation. 
Histopathologic findings of the resected material 
were compatible with mycobacteria infection but 
ZN stains were negative.
The patient’s condition slowly improved and she was 
finally discharged at the end of 2006. She continued 
improving but appearing hypoacusia probably due 
to amikacin which was withdrawn. She completed 
the antimycobacterial treatment prescribed for 
twelve months. Subsequent bacteriological tests, 
during and after the treatment, were negative 
(follow-up until 2008). During 2008, she required a 
reintervention related with her previous ascending 
aortic replacement.
Table 1 shows a summary of the clinical presentation 
and management of the patient.
Discussion
Rapidly growing mycobacteria are microorganisms 
belonging to the non-tuberculous mycobacteria amply 
present in natural (water, soil) or human-influenced 
environments (3). Rapidly growing mycobacteria 
are not usually pathogenic for humans but they can 
cause several type of infections including skin and 
soft tissue infections, osteomyelitis, lymphadenitis, 
disseminated disease, meningitis, postsurgical 
wound infections, infections of prostethic devices, 
and chronic lung disease (3-7,15-18). Some cases 
have been described in Colombia (8,11).
M. peregrinum type III is a rapidly growing 
mycobacteria belonging to the M. fortuitum group (3) 
which also includes M. fortuitum, M. fortuitum third 
variant (19), M. mucogenicum, and M. senegalense. 
Although M. peregrinum was first proposed in 1962, 
only in the last years has been systematicly included 
(20-22). Like other rapidly growing mycobacteria, 
M. peregrinum has been reported as causing skin 
and soft tissue infections, peritonitis (after cancer 
gastric surgery), primary bacteremia, pneumonia, 
tonsillar abscess, catheter-related bacteremia, and 
implantable cardioverter device infection (12,23-
27). Recently, Nagao informed 11 cases reported in 
the literature (12). However, it is possible that some 
other cases had been misclassified as M. fortuitum 
and previously reported (3).
The presence of foreign artificial material (catheter, 
implantable devices) or immunocompromising 
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conditions (HIV infection, infliximab treatment) 
confirm the oportunistic character of M. peregrinum 
and suggest that those conditions favour the 
adherence, colonization, and posterior progression 
of the mycobacteria infection. 
Non-tuberculous mycobacteria colonization and 
infection of intracardiac devices such as prosthetic 
valves, catheters, pacemaker wires or defibrillators 
have been known for long time (15-18). The presence 
in water sources and soil favors the colonization and 
infection of predisposed patients. M. fortuitum group 
may represent 1% to 2% of sporadic community-
acquired or health care-associated infections due 
to rapidly growing mycobacteria (3) and up to 2% 
of in-hospital opportunistic infections (4).
The M. fortuitum group is more sensitive to several 
drugs than other rapidly growing mycobacteria 
making the treatment generally efective (3,7,12,28). 
Some of the effective drugs are: amikacin, imipenem, 
ciprofloxacin, gatifloxacin, levofloxacin, linezolid, 
clarithromycin, trimethoprim-sulfamethoxazole, cefo-
xitin, and doxycycline (3,7,12,28). However, the 
best treatment for M. peregrinum has not been 
established and significant differences may be 
expected among the M. fortuitum group. For 
example, in the case reported by Nagao (12) the 
M. peregrinum was resistant to clarithromycion and 
minocycline. Rapidly growing mycobacteria are 
Table 1. Summary of clinical presentation.
Year Condition Intervention
1989 Birth – murmur found None 
1991 Persistent ductus arteriosus Surgical PDA closure
 Interventricular communication No IVC closure (small) 
1996 Interventricular communication Surgical IVC closure
 Aortic valve and subaortic stenosis Mechanical aortic valve implantation 
2003 Relative prosthetic aortic valve stenosis Surgical change of the mechanical aortic valve
2005 Transient respiratory symptoms Antituberculosis treatment discontinued because of negative  
 Positive Ziehl-Neelsen stain of the sputum bronchoalveolar lavage ZN stain and no parenchymal   
  abnormalities  
2006 Endocarditis involving prosthetic valve Biological aortic valve implantation with ascending aortic
 Positive ZN stain of the sputum replacement
 Positive cultures for rapidly growing mycobacteria  Treatment for rapidly growing mycobacteria-18 months  
 (sputum, blood) 
 M. peregrinum type III identification   
2008 No infectious manifestations Rehabilitation
 Ascending aortic reintervention Ascending aortic reintervention
 Slow recovering and rehabilitation process Follow-up
 Severe hypoacusia
 Negative ZN and mycobacteria cultures
PDA: persistent ductus arteriosus; IVC: interventricular communication; ZN: Ziehl-Neelsen
usually resistant to the common antituberculous 
drugs (isoniazide, for example).
As it has been described for disseminated cases (3), 
our patient was treated with two inyectable drugs: 
amikacin and imipenem, in addition to clarithromycin, 
trimethoprim-sulfamethoxazole, rifampicin, and 
doxicicline.
This is the first case of mycobacteriosis due to M. 
peregrinum type III described in Colombia and the 
first one reported as resulting in a prosthetic valve 
endocarditis, accepting that it is possible that some 
cases previously atributed to M. fortuitum may have 
been caused by M. peregrinum.
In our report, the disseminated condition was 
demonstrated by the isolation of the microorganism 
in sputum and blood samples. The repeatedly 
positive ZN stains of the sputum, with lymphocytosis 
in the bronchoalveolar lavage, and withouth lung 
parenchymal abnormalities suggests a colonization 
and infectious compromise of the upper respiratory 
tract or the tracheobronchial tree (tracheobronchitis). 
The conventional treatment for tuberculosis, as 
expected, was not effective, favoring the subsequent 
dissemination with colonization and infection of 
the prosthetic aortic valve (endocarditis due to M. 
peregrinum). Other manifestations such as the 
purpuric lesions in the legs, arthritis (right knee), 
amaurosis and convulsive crisis can be attributed to 
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the endocarditis rather than direct infection due to 
the mycobacteria. It is difficult to establish the exact 
moment when the respiratory colonization evolved 
into a disseminated disease affecting mainly the 
prosthetic valve (endocarditis).
The persistent presence of positive ZN stain 
without positive cultures for M. tuberculosis, should 
suggest a diagnosis of microorganism containing 
mycolic acids in their walls like non-tuberculous 
mycobacteria, Corynebacterium, Nocardia and 
Rodhococcus (22).
Non-tuberculous mycobacteria, especially rapidly 
growing mycobacteria including M. peregrinum, 
should be considered in patients with insidious 
conditions and chronic use of catheters, prosthetic 
valves, or implantable devices.
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